Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models.

Oxypurinol Polycystic kidney Uric acid Uricase Xanthine oxidase

Journal

American journal of physiology. Renal physiology
ISSN: 1522-1466
Titre abrégé: Am J Physiol Renal Physiol
Pays: United States
ID NLM: 100901990

Informations de publication

Date de publication:
18 Apr 2024
Historique:
medline: 18 4 2024
pubmed: 18 4 2024
entrez: 18 4 2024
Statut: aheadofprint

Résumé

Humans are predisposed to gout because they lack uricase that converts uric acid to allantoin. Rodents have uricase, resulting in low basal serum uric acid. A uricase inhibitor raises serum uric acid in rodents. There were 2 aims of the study in polycystic kidney disease (PKD): 1) to determine whether increasing serum uric acid with the uricase inhibitor, oxonic acid, resulted in faster cyst growth and 2) to determine whether treatment with the xanthine oxidase inhibitor, oxypurinol, reduced the cyst growth caused by oxonic acid. Orthologous models of human PKD were used: PCK rats, a polycystic kidney and hepatic disease 1 (Pkhd1) gene model of autosomal recessive PKD (ARPKD) and

Identifiants

pubmed: 38634129
doi: 10.1152/ajprenal.00372.2023
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : XORTX Therapeutics
ID : NA
Organisme : Zell Family Foundation
ID : NA

Auteurs

Anjana Chaudhary (A)

Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Zhibin He (Z)

Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Daniel J Atwood (DJ)

Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Makoto Miyazaki (M)

Division of Renal Diseases and Hypertension, University of Colorado Denver, Auroa, CO, United States.

Ozgur A Oto (OA)

Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.

Allen Davidoff (A)

XORTX Therapeutics Inc, XORTX Therapeutics Inc, Calgary, Alberta, Canada.

Charles L Edelstein (CL)

Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, Colorado, United States.

Classifications MeSH